A system and method for determining a position of a medical device within a body are provided. The system includes an electronic control unit that receives position signals from position sensors of a first type and a second type disposed on the device and applies a filter to each of the position signals to obtain filtered estimated positions for each sensor. The unit computes a spline connecting the position sensors of the first type responsive to the filtered estimated positions for the sensors and estimates a spline position for the sensor of the second type along the spline. The unit generates maps between the spline position and filtered and unfiltered estimated positions for the sensor of the second type and determines actual positions for the sensors of the first type responsive to the filtered estimated position for the sensors and a composite map of the two maps.

Systems and methods for assessing sympathetic nervous system (SNS) tone for renal neuromodulation therapy are disclosed herein. A system configured in accordance with embodiments of the present technology can include, for example, a detector attached to or implanted in a patient and a receiver communicatively coupled to the detector. The detector can measure cardiac data and the receiver and/or a device communicatively coupled thereto can analyze the cardiac data to provide one or more SNS tone indicators. The SNS tone indicators can be used to determine whether a patient will be responsive to a neuromodulation therapy and/or whether a neuromodulation therapy was effective.

Catheter systems and methods for the selective and rapid application of DC voltage to drive irreversible electroporation are disclosed herein. In some embodiments, an apparatus includes a voltage pulse generator and an electrode controller. The voltage pulse generator is configured to produce a pulsed voltage waveform. The electrode controller is configured to be operably coupled to the voltage pulse generator and a medical device including a series of electrodes. The electrode controller includes a selection module and a pulse delivery module. The selection module is configured to select a subset of electrodes from the series of electrodes. The selection module is configured identify at least one electrode as an anode and at least one electrode as a cathode. The pulse delivery module is configured to deliver an output signal associated with the pulsed voltage waveform to the subset of electrodes.

An ultrasonic apparatus (100) for creating a holographic ultrasound field (1) comprises an ultrasound source device (10) being adapted for creating an ultrasound wave, and a transmission hologram device (20) having a transmission hologram (21) and an exposed acoustic emitter surface (22), said transmission hologram device (20) being acoustically coupled with the ultrasound source device (10) and being arranged for transmitting the ultrasound wave through the acoustic emitter surface (22) and creating the holographic ultrasound field in a surrounding space, wherein the acoustic emitter surface (22) is a smooth surface which do not influence the field distribution of the ultrasound wave. Furthermore, a method of creating a holographic ultrasound field in an object (3), wherein the ultrasonic apparatus (100) is used, and applications of the ultrasonic apparatus (100) are described.

Various devices related to a therapeutic ultrasound device for use during a medical procedure to cauterize tissue are disclosed. The therapeutic ultrasound device can include an inner tube assembly and an outer tube assembly. The device can further include a tissue engagement assembly that is secured to the distal end of the inner tube and the distal end of the outer tube. The tissue engagement assembly includes a plurality of transducers configured to provide therapeutic ultrasound. The device can include a housing assembly that is secured to the proximal end of the inner tube and the proximal end of the outer tube. The housing assembly can include a handle configured to actuate the inner tube relative to the outer tube to engage and disengage the tissue engagement assembly.

The present technology is directed generally to devices, systems, and methods for capturing and cutting fibrous and trabeculated structures (such as synechiae) in vessel lumens. In one embodiment, the present technology includes an intraluminal tissue modifying system configured to capture the fibrous structures, put the fibrous structures in tension, and controllably cut through the fibrous structures without applying appreciable additional force to the vessel wall. The system may include an expandable capture device and a cutting device.

Systems, methods and devices for the treatment of tissue are disclosed. A system includes an elongate tube with a distal portion. A treatment element is positioned on the elongate tube distal portion, the treatment element constructed and arranged to treat target tissue. In one embodiment, gastrointestinal tissue is modified for the treatment of diabetes.

A method of removing microvessels includes applying a burst of acoustic energy at a target location, applying a pulse of optical energy at the target location, and promoting cavitation at the target location. The burst of acoustic energy has a pressure below 5.0 MPa. The pulse of optical energy at the target location has a fluence less than 100 mJ/cm.sup.2. At least a portion of the pulse is concurrent with the burst and the optical energy has an optical area that is overlapping with an acoustic area of the acoustic energy at the target location.

Methods for treating a human patient diagnosed with cancer with therapeutic neuromodulation and associated systems are disclosed herein. Sympathetic nerve activity can contribute to several cellular and physiological processes associated with the progression of cancer. One aspect of the present technology is directed to methods that attenuate neural traffic along target sympathetic nerves innervating tissue proximate a primary malignant tumor. Other aspects are directed to methods that at least partially inhibit sympathetic neural activity in a renal nerve of a patient diagnosed with cancer or who has a high risk of developing cancer. Targeted sympathetic nerve activity can be attenuated to improve a measurable physiological parameter corresponding to the progression of cancer in the patient. The attenuation can be achieved, for example, using an intravascularly positioned catheter carrying a therapeutic assembly, e.g., a therapeutic assembly configured to use electrically-induced, thermally-induced, and/or chemically-induced approaches to modulate the target sympathetic nerve.

Provided is an ultrasonic treatment apparatus provided with: a treatment-ultrasonic-wave irradiator that irradiates the biological tissue with focused ultrasonic waves, thus heating the vicinity of a focal point of the focused ultrasonic waves at a deep portion of the biological tissue to a temperature that is equal to or greater than a thermal-denaturation temperature of the biological tissue; and a pre-heating-energy irradiator that irradiates the biological tissue with energy waves, thus heating the vicinity of the focal point to a temperature that is less than the thermal-denaturation temperature, wherein the pre-heating-energy irradiator irradiates the biological tissue with the energy waves from a direction different from the direction in which the treatment-ultrasonic-wave irradiator irradiates with the focused ultrasonic waves.